Clinical Trial Update: Adding Atomoxetine To Standard Medication Treatment In Patients With Alzheimer's Disease [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 trial evaluated adding atomoxetine to standard treatment in patients with Alzheimer's disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Alzheimer Disease

Drugs mentioned

• Atomoxetine (Atomoxetine)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Alzheimer Disease | Phase 2, Phase 3 | Status: COMPLETED